Condition: Lung Cancer · Breast Cancer · Head and Neck Squamous Cell Carcinoma · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
This study is an open, multicenter, dose-escalation and cohort-expansion non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Lutetium \[177Lu\] BL-ARC001 in patients with locally advanced or metastatic solid tumors.
This description comes directly from the study's public registry record.
Sa Xiao, PHD · 15013238943 · xiaosa@baili-pharm.com
Always discuss trial participation with your own doctor first.
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07274852